Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 123(1): 9-14, 2001 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11167991

RESUMO

MoAbs against tumour-associated antigens (TAA) may be useful for the treatment of colorectal cancer. Since an increased expression of TAA may lead to enhanced antibody-dependent cellular cytotoxicity we examined whether the cytokines IL-2, IL-4, IL-6, IL-10, IL-12, interferon-alpha (IFN-alpha), IFN-gamma, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor and tumour necrosis factor-alpha can influence EpCAM and LewisY expression on the surface of the colorectal carcinoma cell lines HT29, LoVo and SW480. We found that only IFN-alpha increased significantly whereas IL-4 decreased both EpCAM and LewisY expression. IFN-gamma significantly increased LewisY expression only. When tumour cells were treated with MoAb, the LewisY-specific MoAb BR55-2 down-regulated LewisY antigen expression, whereas MoAb 17-1A, which binds to EpCAM, up-regulated this TAA after 3 days of culture. The cytokines IFN-alpha or IFN-gamma combined with MoAb 17-1A enhanced further slightly the expression of EpCAM. In additional experiments with chemotherapeutic drugs commonly used for the treatment of colorectal cancer, we found that 5-fluorouracil, mitomycin-C and oxaliplatin up-regulated EpCAM and LewisY antigen expression. Raltitrexed enhanced LewisY and down-regulated EpCAM expression, whereas CPT-11 had no influence at all. The highest expression for EpCAM on HT29 cells was achieved by the combination of IFN-alpha, 5-fluorouracil and MoAb 17-1A. Our results may be useful for defining combinations of biological and chemotherapeutic drugs for the treatment of colorectal cancer. Further trials should evaluate to what extent these combinations enhance antibody-dependent cellular cytotoxicity.


Assuntos
Anticorpos Monoclonais/fisiologia , Antígenos de Neoplasias/biossíntese , Antineoplásicos/farmacologia , Camptotecina/análogos & derivados , Moléculas de Adesão Celular/biossíntese , Citocinas/fisiologia , Antígenos do Grupo Sanguíneo de Lewis/biossíntese , Adjuvantes Imunológicos/fisiologia , Antígenos de Neoplasias/imunologia , Camptotecina/farmacologia , Moléculas de Adesão Celular/imunologia , Molécula de Adesão da Célula Epitelial , Fluoruracila/farmacologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/fisiologia , Células HT29 , Humanos , Interferons/fisiologia , Interleucinas/fisiologia , Irinotecano , Antígenos do Grupo Sanguíneo de Lewis/imunologia , Fator Estimulador de Colônias de Macrófagos/fisiologia , Mitomicina/farmacologia , Compostos Organoplatínicos/farmacologia , Oxaliplatina , Quinazolinas/farmacologia , Tiofenos/farmacologia , Células Tumorais Cultivadas , Fator de Necrose Tumoral alfa/fisiologia , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...